Literature DB >> 33456984

The Influence of an Elevated Production of Extracellular Enveloped Virions of the Vaccinia Virus on Its Properties in Infected Mice.

S N Shchelkunov1, S N Yakubitskiy1, T V Bauer1, A A Sergeev1, A S Kabanov1, L E Bulichev1, I A Yurganova1, D A Odnoshevskiy1, I V Kolosova1, S A Pyankov1, O S Taranov1.   

Abstract

The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV A34R gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases. Copyright ® 2020 National Research University Higher School of Economics.

Entities:  

Keywords:  immunogenicity; smallpox; vaccine; virulence

Year:  2020        PMID: 33456984      PMCID: PMC7800600          DOI: 10.32607/actanaturae.10972

Source DB:  PubMed          Journal:  Acta Naturae        ISSN: 2075-8251            Impact factor:   1.845


  31 in total

1.  The vaccinia virus B5 protein requires A34 for efficient intracellular trafficking from the endoplasmic reticulum to the site of wrapping and incorporation into progeny virions.

Authors:  Amalia K Earley; Winnie M Chan; Brian M Ward
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

2.  A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.

Authors:  Pragatheeshwar Thirunavukarasu; Magesh Sathaiah; Michael C Gorry; Mark E O'Malley; Roshni Ravindranathan; Frances Austin; Steven H Thorne; Zong Sheng Guo; David L Bartlett
Journal:  Mol Ther       Date:  2013-02-26       Impact factor: 11.454

Review 3.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation.

Authors:  Isabelle Leparc-Goffart; Bertrand Poirier; Daniel Garin; Marie-Hélène Tissier; Florence Fuchs; Jean-Marc Crance
Journal:  J Clin Virol       Date:  2005-01       Impact factor: 3.168

5.  Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene.

Authors:  R Blasco; J R Sisler; B Moss
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

Review 6.  [We should be prepared to smallpox re-emergence.]

Authors:  S N Shchelkunov; G A Shchelkunova
Journal:  Vopr Virusol       Date:  2019

7.  A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.

Authors:  Jennifer Stabenow; R Mark Buller; Jill Schriewer; Cheri West; John E Sagartz; Scott Parker
Journal:  J Virol       Date:  2010-02-03       Impact factor: 6.549

8.  An increasing danger of zoonotic orthopoxvirus infections.

Authors:  Sergei N Shchelkunov
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

9.  Attenuation of Vaccinia Virus.

Authors:  S N Yakubitskiy; I V Kolosova; R A Maksyutov; S N Shchelkunov
Journal:  Acta Naturae       Date:  2015 Oct-Dec       Impact factor: 1.845

View more
  3 in total

1.  Adaptive Immune Response to Vaccinia Virus LIVP Infection of BALB/c Mice and Protection against Lethal Reinfection with Cowpox Virus.

Authors:  Sergei N Shchelkunov; Alexander A Sergeev; Stanislav N Yakubitskiy; Ksenia A Titova; Stepan A Pyankov; Irina V Kolosova; Ekaterina V Starostina; Mariya B Borgoyakova; Alexey M Zadorozhny; Denis N Kisakov; Irina S Shulgina; Larisa I Karpenko
Journal:  Viruses       Date:  2021-08-17       Impact factor: 5.048

2.  Enhancing the Immunogenicity of Vaccinia Virus.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Alexander A Sergeev; Ekaterina V Starostina; Ksenia A Titova; Stepan A Pyankov; Galina A Shchelkunova; Mariya B Borgoyakova; Alexey M Zadorozhny; Lyubov A Orlova; Denis N Kisakov; Larisa I Karpenko
Journal:  Viruses       Date:  2022-06-30       Impact factor: 5.818

3.  Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Kseniya A Titova; Stepan A Pyankov; Alexander A Sergeev
Journal:  Pathogens       Date:  2021-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.